Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis
Authors:
- Ferdinanda AnnesiFAFerdinanda Annesi
- Sonia Hermoso-DuránSHSonia Hermoso-Durán
- Bruno RizzutiBruno Rizzuti
- Rosalinda BrunoRBRosalinda Bruno
- Domenico PirritanoDPDomenico Pirritano
- Alfredo PetroneAPAlfredo Petrone
- Francesco Del GiudiceFGFrancesco Del Giudice
- Jorge OjedaJOJorge Ojeda
- Sonia VegaSVSonia Vega
- Oscar Sanchez-GraciaOSOscar Sanchez-Gracia
- Adrian Velazquez-CampoyAVAdrian Velazquez-Campoy
- Olga AbianOlga Abian
Open Access
- 13 April 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (4) , 295
Abstract
Background: Multiple sclerosis (MS) is frequently characterized by a variety of clinical signs, often exhibiting little specificity. The diagnosis requires a combination of medical observations and instrumental tests, and any support for its objective assessment is helpful. Objective: Herein, we describe the application of thermal liquid biopsy (TLB) of blood plasma samples, a methodology for predicting the occurrence of MS with a noninvasive, quick blood test. Methods: TLB allows one to define an index (TLB score), which provides information about overall real-time alterations in plasma proteome that may be indicative of MS. Results: This pilot study, based on 85 subjects (45 MS patients and 40 controls), showed good performance indexes (sensitivity and specificity both around 70%). The diagnostic methods better discriminate between early stage and low-burden MS patients, and it is not influenced by gender, age, or assumption of therapeutic drugs. TLB is more accurate for patients having low disability level (≤ 3.0, measured by the expanded disability status scale, EDSS) and a relapsing–remitting diagnosis. Conclusion: Our results suggest that TLB can be applied to MS, especially in an initial phase of the disease when diagnosis is difficult and yet more important (in such cases, accuracy of prediction is close to 80%), as well as in personalized patient periodic monitoring. The next step will be determining its utility in differentiating between MS and other disorders, in particular in inflammatory diseases.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18 349, FI19/00146, CPII13/00017)
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (BFU2016-78232-P)
- Gobierno de Aragón (B25_17R to O.A.; E45_17R to A.V.C.)
This publication has 37 references indexed in Scilit:
- Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of NeurodegenerationPLOS ONE, 2014
- Assessing tissue damage in multiple sclerosis: a biomarker approachActa Neurologica Scandinavica, 2014
- Calorimetric monitoring of the serum proteome in schizophrenia patientsThermochimica Acta, 2013
- Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker developmentMultiple Sclerosis Journal, 2013
- The influence of active site loop mutations on the thermal stability of azurin from Pseudomonas aeruginosaArchives of Biochemistry and Biophysics, 2012
- Preliminary use of differential scanning calorimetry of cerebrospinal fluid for the diagnosis of glioblastoma multiformeJournal of Neuro-Oncology, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Calorimetry Outside the Box: A New Window into the Plasma ProteomeBiophysical Journal, 2008
- Proteome-based plasma biomarkers for Alzheimer's diseaseBrain, 2006
- Precise Scanning Calorimeter for Studying Thermal Properties of Biological Macromolecules in Dilute SolutionAnalytical Biochemistry, 1995